DRI HEALTHCARE TRUST (DHT-U.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:DHT-U - CA23344H1091
12.13 USD
+0.29 (+2.45%)
DHT-U gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 31 industry peers in the Pharmaceuticals industry. DHT-U may be in some trouble as it scores bad on both profitability and health. DHT-U is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
DHT-U had positive earnings in the past year.
In the past year DHT-U had a positive cash flow from operations.
1.2 Ratios
With a Return On Assets value of -5.75%, DHT-U perfoms like the industry average, outperforming 54.84% of the companies in the same industry.
DHT-U's Return On Equity of -11.95% is in line compared to the rest of the industry. DHT-U outperforms 54.84% of its industry peers.
The Return On Invested Capital of DHT-U (4.55%) is better than 74.19% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DHT-U is significantly below the industry average of 7.83%.
The last Return On Invested Capital (4.55%) for DHT-U is above the 3 year average (1.94%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.75% | ||
| ROE | -11.95% | ||
| ROIC | 4.55% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
1.3 Margins
DHT-U's Operating Margin of 27.25% is amongst the best of the industry. DHT-U outperforms 96.77% of its industry peers.
In the last couple of years the Operating Margin of DHT-U has declined.
The Profit Margin and Gross Margin are not available for DHT-U so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.25% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DHT-U is destroying value.
DHT-U has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, DHT-U has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.11, we must say that DHT-U is in the distress zone and has some risk of bankruptcy.
DHT-U has a Altman-Z score of 1.11. This is in the better half of the industry: DHT-U outperforms 67.74% of its industry peers.
The Debt to FCF ratio of DHT-U is 4.45, which is a neutral value as it means it would take DHT-U, 4.45 years of fcf income to pay off all of its debts.
DHT-U's Debt to FCF ratio of 4.45 is fine compared to the rest of the industry. DHT-U outperforms 77.42% of its industry peers.
A Debt/Equity ratio of 0.90 indicates that DHT-U is somewhat dependend on debt financing.
DHT-U has a worse Debt to Equity ratio (0.90) than 70.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 1.11 |
ROIC/WACC0.58
WACC7.86%
2.3 Liquidity
DHT-U has a Current Ratio of 1.14. This is a normal value and indicates that DHT-U is financially healthy and should not expect problems in meeting its short term obligations.
DHT-U has a Current ratio of 1.14. This is in the lower half of the industry: DHT-U underperforms 74.19% of its industry peers.
A Quick Ratio of 1.14 indicates that DHT-U should not have too much problems paying its short term obligations.
DHT-U has a Quick ratio (1.14) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
DHT-U shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.41%.
DHT-U shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.09% yearly.
Looking at the last year, DHT-U shows a quite strong growth in Revenue. The Revenue has grown by 16.24% in the last year.
Measured over the past years, DHT-U shows a very strong growth in Revenue. The Revenue has been growing by 32.25% on average per year.
EPS 1Y (TTM)-7.41%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%7%
3.2 Future
The Earnings Per Share is expected to grow by 17.76% on average over the next years. This is quite good.
Based on estimates for the next years, DHT-U will show a quite strong growth in Revenue. The Revenue will grow by 15.26% on average per year.
EPS Next Y-4.49%
EPS Next 2Y3.01%
EPS Next 3Y9.29%
EPS Next 5Y17.76%
Revenue Next Year11.21%
Revenue Next 2Y6.15%
Revenue Next 3Y6.13%
Revenue Next 5Y15.26%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
DHT-U is valuated cheaply with a Price/Earnings ratio of 5.39.
Based on the Price/Earnings ratio, DHT-U is valued cheaper than 90.32% of the companies in the same industry.
DHT-U's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.59.
DHT-U is valuated cheaply with a Price/Forward Earnings ratio of 5.27.
Based on the Price/Forward Earnings ratio, DHT-U is valued cheaply inside the industry as 93.55% of the companies are valued more expensively.
DHT-U's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.80.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.39 | ||
| Fwd PE | 5.27 |
4.2 Price Multiples
DHT-U's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DHT-U is cheaper than 80.65% of the companies in the same industry.
87.10% of the companies in the same industry are more expensive than DHT-U, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.6 | ||
| EV/EBITDA | 7.01 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.01%
EPS Next 3Y9.29%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.57%, DHT-U is a good candidate for dividend investing.
DHT-U's Dividend Yield is rather good when compared to the industry average which is at 3.60. DHT-U pays more dividend than 96.77% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.31, DHT-U pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
5.2 History
DHT-U has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y3.01%
EPS Next 3Y9.29%
TSX:DHT-U (12/10/2025, 7:00:00 PM)
12.13
+0.29 (+2.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners51.1%
Inst Owner ChangeN/A
Ins Owners0.93%
Ins Owner ChangeN/A
Market Cap668.48M
Revenue(TTM)192.69M
Net Income(TTM)-52.23M
Analysts80
Price Target15.56 (28.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.74%
Min EPS beat(2)-4.46%
Max EPS beat(2)0.99%
EPS beat(4)2
Avg EPS beat(4)3.59%
Min EPS beat(4)-21.52%
Max EPS beat(4)39.35%
EPS beat(8)5
Avg EPS beat(8)18.58%
EPS beat(12)6
Avg EPS beat(12)10.35%
EPS beat(16)8
Avg EPS beat(16)65.99%
Revenue beat(2)1
Avg Revenue beat(2)3.28%
Min Revenue beat(2)-0.37%
Max Revenue beat(2)6.93%
Revenue beat(4)2
Avg Revenue beat(4)13.03%
Min Revenue beat(4)-0.64%
Max Revenue beat(4)46.19%
Revenue beat(8)5
Avg Revenue beat(8)25.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.76%
PT rev (3m)6.76%
EPS NQ rev (1m)-2.56%
EPS NQ rev (3m)-2.56%
EPS NY rev (1m)0.1%
EPS NY rev (3m)3.85%
Revenue NQ rev (1m)-2.84%
Revenue NQ rev (3m)-2.84%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)0.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.39 | ||
| Fwd PE | 5.27 | ||
| P/S | 3.47 | ||
| P/FCF | 6.6 | ||
| P/OCF | 6.54 | ||
| P/B | 1.53 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.01 |
EPS(TTM)2.25
EY18.55%
EPS(NY)2.3
Fwd EY18.98%
FCF(TTM)1.84
FCFY15.15%
OCF(TTM)1.86
OCFY15.3%
SpS3.5
BVpS7.93
TBVpS-5.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number20.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.75% | ||
| ROE | -11.95% | ||
| ROCE | 6.33% | ||
| ROIC | 4.55% | ||
| ROICexc | 4.76% | ||
| ROICexgc | 98.84% | ||
| OM | 27.25% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 52.55% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
ROICexc(3y)2.05%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.74%
ROCE(5y)N/A
ROICexgc growth 3Y44.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.25%
ROICexc growth 5YN/A
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 2.53 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 66.17% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 1.11 |
F-Score4
WACC7.86%
ROIC/WACC0.58
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.41%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y-4.49%
EPS Next 2Y3.01%
EPS Next 3Y9.29%
EPS Next 5Y17.76%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%7%
Revenue Next Year11.21%
Revenue Next 2Y6.15%
Revenue Next 3Y6.13%
Revenue Next 5Y15.26%
EBIT growth 1Y343.32%
EBIT growth 3Y24.15%
EBIT growth 5YN/A
EBIT Next Year107.92%
EBIT Next 3Y27.94%
EBIT Next 5Y29.01%
FCF growth 1Y103.46%
FCF growth 3Y19.16%
FCF growth 5YN/A
OCF growth 1Y103.46%
OCF growth 3Y19.16%
OCF growth 5YN/A
DRI HEALTHCARE TRUST / DHT-U.CA FAQ
What does DHT-U do?
DRI Healthcare Trust is an unincorporated open-ended company. The company is headquartered in Toronto, Ontario and currently employs 36 full-time employees. The company went IPO on 2021-02-11. The firm provides capital to universities and research institutions, academic institutions, biotechnology companies and pharmaceutical companies. The company acquires more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, and other products. Its therapeutic areas include oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders (LSD) and immunology. The firm is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Galderma, and others.
What is the current price of DHT-U stock?
The current stock price of DHT-U.CA is 12.13 USD. The price increased by 2.45% in the last trading session.
How is the ChartMill rating for DRI HEALTHCARE TRUST?
DHT-U.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.